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Background: Recent research has demonstrated the potential of 18-kDa translocator protein (TSPO) to serve as a
target for nuclear imaging of gliomas. The aim of this study was to evaluate SPECT imaging of GL26 mouse glioma
using radioiodinated CLINDE, a TSPO-specific tracer.
Methods: GL26 cells, previously transfected with an enhanced green fluorescent protein (EGFP)-expressing
lentivirus, were stereotactically implanted in the striatum of C57/Bl6 mice. At 4 weeks post-injection, dynamic SPECT
scans with [123I]CLINDE were performed. A displacement study assessed specificity of tracer binding. SPECT images
were compared to results of autoradiography, fluorescence microscopy, in situ nucleic acid hybridization, histology,
and immunohistochemistry. Western blotting was performed to verify TSPO production by the tumor.
Results: Specific uptake of tracer by the tumor is observed with a high signal-to-noise ratio. Tracer uptake by the
tumor is indeed 3.26 ± 0.32 times higher than that of the contralateral striatum, and 78% of the activity is displaceable
by unlabeled CLINDE. Finally, TSPO is abundantly expressed by the GL26 cells.
Conclusions: The present study demonstrates the feasibility of [123I]CLINDE SPECT in translational studies and
underlines its potential for clinical glioma SPECT imaging.
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The 18-kDa translocator protein (TSPO) is primarily lo-
cated at the contact sites between the inner and outer
mitochondrial membranes, as a component of the mito-
chondrial permeability transition pore. Although its ex-
pression in healthy brain is minimal, it increases
substantially in neuroinflammatory conditions [1] as well
as in brain malignancies [2-4]. In the case of brain tu-
mors, TSPO is predominantly expressed by neoplastic
cells, thus, it is regarded as a potential central nervous
system (CNS) cancer imaging biomarker.
Radioiodinated CLINDE is a highly-specific SPECT
TSPO tracer that has been already evaluated in animal* Correspondence: philippe.millet@hcuge.ch
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study was to investigate the potential use of radioiodi-
nated CLINDE as a brain tumor SPECT imaging tracer
in the mouse GL26 glioma model using in vivo high-
resolution SPECT [7]. To validate our approach, we 1)
compared in vivo measurements to ex vivo autoradiog-
raphy and histology; 2) evaluated the specificity of tracer
binding (in vivo displacement procedure); and 3) con-
firmed the presence of TSPO mRNA by means of in situ
hybridization, as well as TSPO protein levels produced
by the tumor by means of immunohistochemistry and
western blotting, respectively.Methods
All chemicals were purchased from Sigma-Aldrich (St.
Gallen, Switzerland), unless otherwise specified. CLINDE
precursor was provided by the Australian Nuclear Sci-
ence and Technology Organization (ANSTO).s an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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Prof. L. Zitvogel (Institut G. Roussy, Paris, France). They
were routinely cultured in DMEM, supplemented with
10% fetal bovine serum (FBS) and 1 mM sodium pyru-
vate (Life technologies, Zug, Switzerland). A stable GL26
cell line expressing enhanced green fluorescent protein
(EGFP) was obtained by a lentiviral vector transfection
according to the manufacturer instructions (ViraPower
Lentiviral Expression System, Life technologies, Zug,
Switzerland). Blasticidin (from 2 to 5 μg/ml of culture
medium during 2 weeks) was used for the selection of
clone of GL26 cells expressing EGFP. GL26-EGFP cells
(50.000 cells in 2.5 μl of culture medium/injection) were
stereotactically implanted in the striatum of adult male
C57/Bl6 mice (Janvier Laboratories, Saint Berthevin,
France, n = 10), weighing 28.2 ± 3.2 g, under isoflurane
(4% induction and 1.5% to 2% maintenance) anesthesia.
Three of these animals received a concurrent second in-
jection of culture medium only in the contralateral stri-
atum. All animal experiments were approved by the
Animal Ethics Committee of the Canton of Geneva and
were in accordance with the European Union regulations
on animal research.
[123I]CLINDE were labeled as previously described [8].
At 4 weeks post-injection, mice were injected with 62.24
± 18.90 MBq of radiotracer and underwent a dynamic
SPECT session with the U-SPECT-II scanner (MILABS,
Utrecht, Netherlands), using a list mode acquisition proto-
col consisting of 60 frames of 84 s. For the displacement
study, four out of ten mice were injected with unlabeled
CLINDE (10 mg/kg) at the 82th minute post-injection of
the labeled tracer. Total scan duration was 165 min.
SPECT tomograms were reconstructed with an or-
dered subsets expectation maximization (OSEM) algo-
rithm (using four subsets and six iterations). SPECT
data were corrected for radioactive decay, but no correc-
tion of attenuation and scatter was applied. A 0.4-mm
FWHM filter was applied on images. The dynamic
SPECT images were first averaged over time frames be-
tween 50 and 80 min in order to enhance visualization
of the different structures. These images were manually
co-registered to a mouse magnetic resonance imaging
(MRI) and volume of interest (VOI) template [9] that
was implemented in PMOD software (version 3.6, 2014,
PMOD Technologies Ltd, Zurich, Switzerland), and the
co-registration parameters were employed for dynamic
image co-registration. Standardized uptake values (SUV)
of tumor and contralateral striatum radioactivity were
extracted from averaged frames between 50 and 80 min,
using PMOD and compared by means of t-test (Micro-
soft Excel, 14.4.7).
Mice were sacrificed after the end of the scan session
at 4 weeks post-implantation of GL26 cells. Brains were
harvested and frozen in isopentane (−20°C) and serialcoronal sections were taken. Brain sections were used
for ex vivo autoradiography, fluorescence microscopy,
Nissl staining, immunohistochemistry, and in situ
hybridization. Two digoxigenin-labeled riboprobes com-
plementary to the Mus musculus translocator protein
(TSPO) mRNA sequences (NM-00977.4: coding se-
quences 102-380 and 322-577, respectively) were used.
The cDNA amplicons from total RNA extracted from a
mouse brain cortex were inserted in a TOPO-pCR4 vec-
tor (Invitrogen, Carlsbad, CA, USA) followed by
linearization and in vitro transcription in presence of
dUTP-digoxigenin (Roche, Basel, Switzerland) according
to the manufacturer instructions (Invitrogen, Carlsbad,
CA, USA). The in situ hybridization histochemistry pro-
cedures were previously reported in detail [10]. The use
of sense probes, in serial tissue sections, resulted in the
absence of any hybridizing signal whereas the two anti-
sense independent probes mentioned above gave the
same patterns of labeling. Thus, these data were in favor
of the specificity of the hybridizing signal for TSPO
mRNA visualized in the tumor tissue sections. TSPO-
immunoreactivity expressed by glioma cells was further
suggested by immunohistochemistry and the TSPO-
immunoreactive band seen in a Western blot using an
anti-TSPO antibody (goat anti-mouse TSPO antibody
LS-B5755, LifeSpan Biosciences, Inc., Seattle, WA, USA;
working dilution 1:1,000). The Western blotting proced-
ure was published with detail elsewhere [11].
Results
Figure 1A,B,C shows an in vivo SPECT image (averaged
over frames corresponding to 50 to 80 min post-injection
of tracer), co-registered to the mouse MRI template. A
corresponding coronal brain section after ex vivo autoradi-
ography is presented in Figure 1D. Figure 2 (left part) il-
lustrates the tissue-activity curves (TACs) extracted from
the dynamic images of seven mice using two circular VOIs
manually delineated on the tumor as well as an equal size
VOI on the contralateral striatum. A rapid tracer uptake is
observed in the initial frames post-injection followed by
washout that, for the contralateral VOI, is almost
complete and rapid. Analysis of averaged image frames be-
tween 50 and 80 min post-injection across different ex-
perimental subjects demonstrated that the tumor side
(mean SUV 1.04 ± 0.22) presents a level of radioactivity
3.26 ± 0.32 times higher than that of the contralateral side
(mean SUV 0.32 ± 0.08, p < 0.001). TACs of the dynamic
scan presented in Figure 2 (right part) also depict the re-
sult of a displacement experiment in which 10 mg/kg of
unlabeled compound were injected at 82 min post-
injection. Radioactivity kinetic pattern in the tumor VOI
reveals that about 78% of the radioactivity is displaceable.
Figure 3A presents a coronal section of a tumor-bearing
mouse after Nissl staining while Figure 3B depicts brain
Figure 1 In vivo SPECT imaging, histology and ex vivo autoradiography. In vivo SPECT image (summed frames between 50 and 80 min of
scan), co-registered with a mouse brain MRI template, obtained from one mouse bearing the GL26 tumor in the coronal (A), sagittal (B), and axial
(C) planes. VOIs corresponding to tumor and contralateral brain tissue are also depicted. (D) Ex vivo autoradiography of a corresponding brain
section from the same mouse. Color scale refers to percentage of maximal activity in the image.
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of fluorescence microscopy and (Figure 3C) in situ
hybridization with specific probes that demonstrate the
expression of the TSPO mRNA by the tumor.
Finally, immunohistochemical analysis (Figure 4A)
shows TSPO-immunoreactivity in most of the tumor
cells. Western blotting (Figure 4B) analyses of tumor tis-
sue extracts compared to spleen extracts (as positive
control) show a similar 18-kDa band confirming the
presence of TSPO protein in these cell populations.Figure 2 Time-activity curves and displacement experiments. TACs, corr
mouse and an equal volume VOI placed on the contralateral hemisphere (left
Displacement with a saturating concentration of unlabeled CLINDE (10 mg/kg
activity is displaceable, suggesting a significant proportion of specific bindingDiscussion
Standard clinical practice in brain tumor imaging in-
cludes MRI that is considered the ‘gold standard’ pre-
senting high spatial resolution but failing to provide
sufficient information on the histopathological and mo-
lecular profile of the malignant lesions [12]. On the con-
trary, nuclear imaging approaches such as positron
emission tomography (PET) and SPECT may provide in-
formation on functional features of the disease such as
metabolic activity and the expression of moleculesesponding to an oval-shaped VOI defined manually on the tumor of this
part, data represent mean ± SD of results from seven mice).
) was performed at 82 min of scan demonstrating that about 78% of the
(right part, data represent mean ± SD of results from four mice).
Figure 3 Fluorescence microscopy and in situ mRNA hybridization. (A) Coronal brain section of GL-26 tumor-bearing mouse visualized after
Nissl staining. (B) A coronal brain section of another mouse visualized under fluorescence microscopy depicting the EGFP-expressing GL26 cells.
(C) Result of in situ TSPO mRNA hybridization performed on an adjacent brain section (box depicts part of the slice in a greater magnification).
Figure 4 Immunohistochemistry and Western blotting. (A) Immunohistochemical analysis of a brain section from a mouse showing TSPO
expression by tumor cells. (B) Western blotting assay demonstrates TSPO expression from GL26 tumor tissue (gl) as compared to spleen tissue
(sp), used as a positive control. Molecular weight of the bands corresponds to 18 kDa, as demonstrated with the use of a molecular weight probe
(left-most column).
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cesses of the CNS, one of them being TSPO. There is
now evidence that TSPO expression might serve as a
biomarker of tumor progression, metastatic potential,
and overall prognosis in several human tumors [13].
TSPO imaging in glioma has already been assessed
using PET through a series of studies using different
[11C]- or [18 F]-labeled tracers [2-4,14]. Buck et al. [14]
showed specific [18 F]PBR06 uptake that closely correlated
with TSPO expression in a rat glioma model. Similarly, [18
F]DPA-714 preclinical imaging in rat models gave encour-
aging results [2,3]. Winkeler et al. [2] showed that neo-
plastic cells produce the majority of TSPO expressed by
the tumor. In this study, TSPO expression by GL26 cells,
as assessed by means of in situ hybridization for TSPO
mRNA and fluorescence microscopy, supports the afore-
mentioned observation.
Our study highlights the potential of SPECT imaging in
clinical neuro-oncology. In fact, SPECT is frequently
employed in clinical neuroscience: in the domain of neuro-
oncology, recent meta-analyses of clinical studies demon-
strate that SPECT, due to its high specificity, is perhaps the
best imaging modality to differentiate between cerebral re-
gions due to tumor recurrence or radiotherapy-induced
necrosis [15,16]. Regarding TSPO imaging in particular,
Awde et al. proposed that TSPO imaging could serve as a
molecular biomarker of glioma progression and even re-
sponse to treatment [17]. However, regarding human gli-
oma imaging using TSPO-specific radiotracers, one has to
take into account that not all types of glioma show equally
high levels of TSPO expression as glioblastoma [4,18] and
this element could be exploited for the differential diagno-
sis of different types of these tumors. In addition, funda-
mental differences between SPECT and PET render the
former much more readily available in clinical settings due
to the long half-lives of radionuclides employed in SPECT
(e.g., 13.2 h for 123I compared to 110 min for 18F and
20 min for 11C, two widely employed PET radionuclides)
and its lower cost. Similarly, in the experimental level, the
emergence of new preclinical SPECT scanners provides
sub-millimeter spatial resolution, superior to that of small
animal PET and has rendered SPECT a particularly power-
ful tool for small animal research [19]. This, along with the
aforementioned advantages of SPECT in the practical level
(availability of radionuclides, lower cost), propose that
employing radioiodinated CLINDE could be considered an
attractive alternative to PET TSPO tracers already de-
scribed above, in experimental and - potentially - in clinical
settings. Indeed, in the present study, we demonstrate a
specific binding of radioiodinated CLINDE to GL26 gli-
oma, where TSPO expression is abundant. Tracer uptake
by the tumor is 3.26 times higher than in the contralateral
hemisphere, indicating a good signal-to-noise ratio. In vivo
SPECT images, ex vivo autoradiography, and fluorescencemicroscopy show comparable results regarding tumor
anatomy. A displacement study confirmed the specificity
of tracer binding on TSPO as about 78% of the activity in
the tumor was displaceable by the unlabeled compound. In
Figure 2 (right part), an augmentation of the activity in the
striatum that is contralateral to the one with the tumor
after displacement with CLINDE is observed. It could be
attributed to a displacement of the radiotracer from extra-
cerebral tissues where TSPO expression is abundant [1]
and entry into the brain. Finally, tracer uptake from tumor
is not attributable to the lesion produced by the stereotac-
tic injection of GL26 cells, as contralateral striatum,
injected with culture medium alone, did not reveal but a
negligible uptake (data not shown).
Conclusions
To our knowledge, this is the first study on a potential
TSPO SPECT glioma tracer. We believe that, given its
specificity and its signal-to-noise ratio, our results dem-
onstrate the quality of [123I]CLINDE SPECT imaging of
glioma in translational studies and are indicative of its
potential value in a clinical setting.
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